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COVID-19 in the Pediatric Population
Wuhan Study January & February 2020
• Largest cohort of children studied to date (2143)
• Patients divided into categories based on severity and progression of symptoms:
• Asymptomatic: picked up by screening with no symptoms
• Mild Disease: symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore 
throat, runny nose, and sneezing. Physical examination shows congestion of the pharynx and no auscultory 
abnormalities. Some cases may have no fever, or have only digestive symptoms such as nausea, vomiting, abdominal 
pain and diarrhea. 
• Moderate Disease: with pneumonia, frequent fever and cough, mostly dry cough, followed by productive cough , 
some may have wheezing, but no obvious hypoxemia such as shortness of breath 
• *Severe Disease: Early respiratory symptoms such as fever and cough, may be accompanied by gastrointestinal 
symptoms such as diarrhea. The disease usually progresses around 1 week, and dyspnea occurs, with central 
cyanosis. Oxygen saturation is less than 92%, with other hypoxia manifestation 
• *Critical: Children can quickly progress to acute respiratory distress syndrome (ARDS) or respiratory failure, and may 
also have shock, encephalopathy, myocardial injury or heart failure, coagulation dysfunction, and acute kidney injury. 
Organ dysfunction can be life threatening. 
* Require Hospitalization
Dona, Y., Mo, X., Hu, Y, et al, Epidemiology and characteristics of 2143 pediatric patients 




• All ages are susceptible to COVID-19
• Children may have GI symptoms (diarrhea, 
vomiting, abdominal pain), in addition to 
respiratory symptoms
• Majority of pediatric patients (94%) were in the 
asymptomatic, mild or moderate categories (no 
hospitalization); Of those with severe or critical 
disease over 50% were under 12 mos.
• Majority of children recover after 1-2 weeks
• Infants (<1 year) are vulnerable and susceptible 
to severe disease
• Children can serve as asymptomatic vectors 





• Case reports of newborns with high viral loads of 
COVID-19 but are clinically asymptomatic
• Theories:
• Young children are developing immunity to 
many different viruses, and thus have high 
levels of antibodies that cross-react with 
COVID-19
• Young children have something 
fundamentally different about their immune 
system that allows them to mount a more 






• No clinical management guidelines established 
yet; They will be forthcoming as we study more 
patients
• Patients at risk for severe disease: 
• Children under 12 months  of age
• Children with asthma and other chronic 
underlying diseases 
(cardiac disease, diabetes)







Some clinical issues that have been raised in the U.S.
• Steroids: not indicated at this time for children
• Albuterol: Helpful for patients with asthma; 
Metered dose inhalers should be used instead of 
nebulizers in COVID19 positive patients, to 
minimize aerosolized spread of virus
• Ibuprofen :  Reports of association of more severe 
disease in children who used  ibuprofen- these 
reports have not been supported by WHO or FDA
• Chloroquine/ azithromycin: Reports of clinical 
improvement in patients taking this combination 
of antibiotics – These finding not supported by 
evidence and could be dangerous to patients 
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